[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The General Hospital of Western Theater Command\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":291},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,42,70,96,118,141,165,184,209,232,269],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100644809","early-phase-1-ebv-mrna-vaccine-for-the-prevention-of-ebv-related-diseases-after-allo-hsct-100644809",false,"NCT07674199","EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allo-HSCT","An Exploratory Study of EBV mRNA Vaccine for the Prevention of EBV-Related Diseases After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\n* Age ≥14 years, regardless of gender;\n* Patients undergoing allogeneic hematopoietic stem cell transplantation;\n* Voluntary participation in the clinical study and signing of the informed consent form.\n\nExclusion Criteria:\n\n* History of vaccine allergy;\n* Presence of active acute graft-versus-host disease (aGVHD) at screening;\n* Severe impairment of cardiac, hepatic, or renal function;\n* Body temperature \\>38°C within 72 hours prior to enrollment;\n* Inability to communicate reliably with the investigator or unlikely to comply with study requirements;\n* Any other condition deemed by the investigator to make the patient unsuitable for enrollment.","ALL","14 Years",{"count":19,"type":20},20,"ESTIMATED","INTERVENTIONAL",[23],"EARLY_PHASE1","The purpose of this clinical trial is to investigate the efficacy of the EBV mRNA vaccine (WGc-0401 injection) in preventing EBV-related diseases after allogeneic hematopoietic stem cell transplantation (allo-HSCT), and to evaluate the safety and efficacy of this vaccine in patients following allo-HSCT.\n\nThe main study questions are:\n\n1. The incidence of grade III-IV acute graft-versus-host disease (aGVHD) within 100 days, and the occurrence of ≥ grade 3 adverse events (AEs) that are possibly or definitely related to the vaccine, in patients receiving EBV mRNA vaccination after allo-HSCT.\n2. To determine the optimal biological dose (OBD) of the EBV mRNA vaccine in patients after allo-HSCT among the dose levels of 25μg, 50μg, 75μg, or 100μg.\n3. EBV-ELISpot levels, the incidence of EBV viremia (EBV DNAemia), the incidence of post-transplant lymphoproliferative disorders (PTLD), disease relapse rate during follow-up, non-relapse mortality (NRM), and immunogenicity indicators (IFN-γ+ T cells, immune cell analysis, cytokine profiles, EBV glycoprotein antigen antibodies).\n\nParticipants will:\n\n1. Receive three intramuscular injections of the EBV mRNA vaccine on days 30, 44, and 81 after allogeneic hematopoietic stem cell transplantation (d30, d44, d81).\n2. Be hospitalized for at least 72 hours after each vaccination for close monitoring (with a focus on CRS and aGVHD), and undergo intensive safety assessments throughout the dose-escalation period (at least 28 days).\n3. Return for clinical visits on days 7 (d37, d51, d88), day 14 (d58), and day 180 (d180) after vaccination for EBV-ELISpot, EBV-DNA quantification, and immunogenicity testing, with continued long-term follow-up to evaluate safety and the persistence of vaccine-induced immune responses.",[26],"Patients After Hematopoietic Stem Cell Transplantation",[28],"HSCT","NOT_YET_RECRUITING","2026-06-23",{"date":32,"type":33},"2026-06-29","ACTUAL",{"date":35,"type":20},"2026-06-18",{"date":37,"type":20},"2031-12-31",{"name":39,"class":40},"The General Hospital of Western Theater Command","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":21,"phases":52,"briefSummary":53,"conditions":54,"keywords":56,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":41},"100632861","early-phase-1-car-70-bcma-car-t-cells-for-the-treatment-of-relapsed-or-refractory-plasma-cell-neoplasms-100632861","NCT07519187","CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms","Clinical Study on the Safety and Efficacy of CAR 70-BCMA Dual-Target CAR-T Therapy for Relapsed or Refractory Plasma Cell Neoplasms","Inclusion Criteria:\n\n1. The subject or their legally authorized representative has provided written informed consent and is willing and able to comply with scheduled visits, study treatment, laboratory tests, and other study procedures\n2. Diagnosis of relapsed or refractory plasma cell neoplasms, defined as follows:\n\n   * Clonal plasma cells positive for BCMA and\u002For CD70 expression as determined by flow cytometry or immunohistochemistry\n   * Patients with multiple myeloma, plasmacytoma, or plasma cell leukemia who have received at least three prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR\n   * Patients with systemic light chain amyloidosis who have received at least two prior lines of therapy, including an anti-CD38 monoclonal antibody and either a proteasome inhibitor (PI) or an immunomodulatory agent (IMiD), and whose best response was less than partial response (PR) or who experienced disease progression after achieving at least PR\n3. Aged 18 to 75 years (inclusive), male or female\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n5. Life expectancy greater than 3 months from the date of informed consent\n6. Hemoglobin (HGB) ≥ 60 g\u002FL (transfusion permitted)\n7. Adequate hepatic, renal, cardiac, and pulmonary function meeting the following criteria:\n\n   * Creatinine ≤ 2 × upper limit of normal (ULN)\n   * Left ventricular ejection fraction (LVEF) ≥ 50%\n   * Oxygen saturation \\> 90%\n   * Total bilirubin ≤ 1.5 × ULN; alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN\n8. The subject agrees to use contraceptive measures from the time of signing the informed consent form until 1 year after CAR-T cell infusion\n\nExclusion Criteria:\n\n* Severe cardiac dysfunction with left ventricular ejection fraction (LVEF) \\\u003C 50%\n* History of severe pulmonary function impairment\n* Concurrent progressive malignancy\n* Concurrent severe infection that cannot be adequately controlled\n* Concurrent severe autoimmune disease or congenital immunodeficiency\n* Active hepatitis, defined as hepatitis B virus deoxyribonucleic acid (HBV-DNA) or hepatitis C virus ribonucleic acid (HCV-RNA) above the lower limit of detection\n* Human immunodeficiency virus (HIV) infection or known acquired immunodeficiency syndrome (AIDS), or syphilis infection\n* History of severe allergic reaction to biological products (including antibiotics)\n* Patients who have undergone allogeneic hematopoietic stem cell transplantation and still have acute graft-versus-host disease (GVHD) one month after discontinuation of immunosuppressive agents\n* Presence of any other serious physical or mental illness, or laboratory abnormality that may increase the risk of study participation, interfere with the interpretation of study results, or render the patient unsuitable for study enrollment in the opinion of the investigator\n* Female patients of childbearing potential who are pregnant or breastfeeding","18 Years","75 Years",{"count":19,"type":20},[23],"This is a single arm study to evaluate the safety and efficacy of CAR70-BCMA dual-target CAR-T cell therapy for relapsed and refractory plasma cell neoplasms.",[55],"Relapsed or Refractory Plasma Cell Neoplasms",[57,58,59,60],"Relapsed and Refractory Plasma Cell Neoplasms.","BCMA","CD70","CAR-T","RECRUITING","2026-06-05",{"date":64,"type":33},"2026-06-09",{"date":66,"type":33},"2026-04-23",{"date":68,"type":20},"2028-04-01",{"name":39,"class":40},{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":85,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":92,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100638225","phase-1-a-clinical-study-to-evaluate-jcxh-213-in-the-treatment-of-adults-with-primary-immune-thrombocytopenia-100638225","NCT07622329","A Clinical Study to Evaluate JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia","An Open-label, Single-arm, Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of JCXH-213 in the Treatment of Adults With Primary Immune Thrombocytopenia","Inclusion Criteria\n\n1. Voluntarily sign the informed consent form (ICF) and be expected to complete the follow-up visits and treatment required by the study protocol.\n2. Age ≥ 18 years and ≤ 65 years at screening, male or female.\n3. Clinical diagnosis of primary immune thrombocytopenia (ITP) for no less than 3 months, according to the American Society of Hematology 2011 Evidence-Based Practice Guideline (Neunert et al. 2011) or the International Consensus Report on the Investigation and Management of Primary Immune Thrombocytopenia (Provan et al. 2010), as applicable.\n\n   Failure (ineffective, loss of maintenance of response, or relapse) of corticosteroid therapy and failure (ineffective, loss of maintenance of response, or relapse) or intolerance to at least one second-line ITP therapy.\n4. At least one second-line ITP therapy includes: rituximab and\u002For recombinant human thrombopoietin (rhTPO, e.g., TPO), thrombopoietin receptor agonists (TPO-RA, e.g., eltrombopag, hetrombopag, avatrombopag, romiplostim).\n\n   Ineffectiveness is defined as platelet count \\\u003C 30 × 10⁹\u002FL after receiving the following treatments:\n\n   Rituximab: 375 mg\u002Fm² once weekly for 4 doses; rhTPO: 300 U\u002Fkg\u002Fday for more than 14 days; Eltrombopag: 75 mg\u002Fday for more than 28 days; Hetrombopag: 7.5 mg\u002Fday for more than 28 days; Avatrombopag: 60 mg\u002Fday for more than 28 days; Romiplostim: up to a maximum weekly dose of 10 μg\u002Fkg for more than 28 days.\n5. Platelet count \\\u003C 30 × 10⁹\u002FL within 48 hours prior to the first dose of study drug (at least two consecutive platelet counts \\\u003C 30 × 10⁹\u002FL, at least 1 day apart, during screening and\u002For prior to first dose).\n6. Eastern Cooperative Oncology Group (ECOG) performance status score of 0-2.\n7. Patients receiving stable-dose maintenance therapy, including corticosteroids (not exceeding 0.5 mg\u002Fkg\u002Fday prednisone or equivalent) or thrombopoietin receptor agonists, may be enrolled, provided that the patient is on only one concomitant medication with stable dose and frequency, and the concomitant medication has been stable for at least 4 weeks prior to the first infusion of study drug.\n8. Adequate organ function, meeting the following laboratory criteria:\n\n   Coagulation function:\n\n   Activated partial thromboplastin time (APTT) ≤ 1.5 × upper limit of normal (ULN) Prothrombin time (PT) ≤ 1.5 × ULN\n\n   Liver function:\n\n   Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN Total bilirubin ≤ 1.5 × ULN, unless documented Gilbert's syndrome Patients with Gilbert-Meulengracht syndrome may be included if total bilirubin ≤ 3.0 × ULN and direct bilirubin ≤ 1.5 × ULN\n\n   Renal function:\n\n   Serum creatinine ≤ 1.5 × ULN, or creatinine clearance ≥ 60 mL\u002Fmin (Cockcroft-Gault formula; see Appendix 1)\n\n   Hematology (without blood transfusion, platelet transfusion, or growth factor use within 7 days prior to screening hematology assessment):\n\n   Hemoglobin ≥ 80 g\u002FL Absolute neutrophil count (ANC) ≥ 1.0 × 10⁹\u002FL Absolute lymphocyte count (LY) ≥ 0.5 × 10⁹\u002FL\n\n   Cardiopulmonary function:\n\n   Left ventricular ejection fraction (LVEF) ≥ 45% Oxygen saturation ≥ 91% without supplemental oxygen\n9. Female patients of childbearing potential must have a negative pregnancy test at screening. Any male or female patient of childbearing potential must agree to use effective contraceptive methods from the time of signing the ICF through at least 6 months after the last infusion of JCXH-213.\n\nFemale patients not of childbearing potential must meet at least one of the following criteria:\n\nHave undergone hysterectomy, bilateral salpingectomy, or bilateral oophorectomy; Medically confirmed postmenopausal (at least 12 consecutive months of amenorrhea without pathological or physiological cause, with reproductive status assessed by hormone levels if necessary).\n\nExclusion Criteria\n\n1. Diagnosis of autoimmune hemolytic anemia, any secondary or hereditary thrombocytopenic disorders, including leukemia, lymphoma, multiple myeloma, aplastic anemia, myelodysplastic syndrome, Evans syndrome, common variable immunodeficiency, systemic lupus erythematosus, liver cirrhosis, antiphospholipid syndrome, pseudothrombocytopenia, or drug-induced thrombocytopenia (e.g., due to quinine, heparin, antibiotics, or antiepileptic drugs).\n2. History of any thromboembolic event or extensive\u002Fsevere bleeding within 1 year prior to the first dose of study drug, such as hemoptysis, major upper gastrointestinal bleeding, intracranial hemorrhage, or presence of sepsis or other irregular bleeding.\n3. Receipt of anti-CD20 monoclonal antibody (e.g., rituximab) or other medicinal treatments (including cyclophosphamide and vindesine) within 3 months prior to the first dose of study drug.\n4. Receipt of the following medicinal treatments within 4 weeks prior to the first dose of study drug: azathioprine, danazol, dapsone, cyclosporine A, tacrolimus, or sirolimus.\n5. Use of anticoagulants or any antiplatelet agents (e.g., aspirin) within 3 weeks prior to the first dose of study drug.\n6. Receipt of emergency treatment for ITP (e.g., methylprednisolone, platelet transfusion, intravenous immunoglobulin, or TPO-RA) within 2 weeks prior to the first dose of study drug.\n7. Splenectomy within 6 months prior to the first dose of study drug.\n8. History of malignancy within 5 years prior to screening, with the exception of adequately treated cervical carcinoma in situ, basal cell or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, ductal carcinoma in situ after radical surgery, or thyroid cancer after radical surgery.\n9. Any unstable systemic disease, including but not limited to: uncontrolled active infection (excluding local infection); unstable angina pectoris; cerebrovascular accident or transient ischemic attack (within 6 months prior to screening); myocardial infarction or history of coronary angioplasty or stenting (within 6 months prior to screening); New York Heart Association (NYHA) Class III or IV cardiac insufficiency; refractory hypertension (defined as blood pressure not controlled after more than 1 month of treatment with ≥ 3 antihypertensive drugs \\[including diuretics\\] at reasonable and tolerable doses after lifestyle modification, or requiring ≥ 4 antihypertensive drugs to achieve blood pressure control); severe cardiac arrhythmia requiring medication; or significant hepatic, renal, or metabolic disease.\n10. Known or suspected history of immunosuppression, including invasive opportunistic infections such as histoplasmosis, coccidioidomycosis, coccidiosis, Pneumocystis jirovecii pneumonia, and aspergillosis, even if the infection has resolved; or unusually frequent, recurrent, or prolonged infections, as judged by the investigator.\n11. Positive peripheral blood test for hepatitis B virus (HBV) DNA; positive hepatitis C virus (HCV) antibody with positive peripheral blood HCV RNA; positive human immunodeficiency virus (HIV) antibody; positive cytomegalovirus (CMV) DNA; or positive Treponema pallidum test.\n12. Prior receipt of organ transplantation, or planned organ transplantation during the study period.\n13. Prior receipt of CAR-T therapy within 3 months.\n14. Active autoimmune or inflammatory neurological disorder (e.g., Guillain-Barré syndrome, amyotrophic lateral sclerosis).\n15. Clinically significant active cerebrovascular disease (e.g., cerebral edema, posterior reversible encephalopathy syndrome).\n16. Life expectancy of less than 3 months.\n17. Participation in another interventional clinical study and receipt of investigational drug within 1 month prior to enrollment (for marketed drugs, or investigational drugs with a known half-life, the shorter of 5 half-lives or 2 weeks applies).\n18. Receipt of live attenuated vaccine within 6 weeks prior to screening, or planned receipt of live attenuated vaccine during the study period.\n19. Contraindication or hypersensitivity to tocilizumab; contraindication or hypersensitivity to any component of the investigational product, JCXH-213.\n20. Pregnant or lactating women, or women planning to become pregnant or breastfeed from the time of signing the ICF through 6 months after the last infusion of JCXH-213; or male patients whose partner plans to become pregnant during this period.\n21. Any contraindication to any study procedure or other medical condition that, in the investigator's judgment and\u002For according to clinical standards, would place the patient at unacceptable risk.","65 Years",{"count":79,"type":20},4,[81],"PHASE1","This is an open-label, single-arm, dose-escalation study designed to evaluate the safety, tolerability, recommended subsequent dose, pharmacokinetic profile, and preliminary efficacy of JCXH-213 in adult patients with primary immune thrombocytopenia (ITP) who are refractory or relapsed after treatment with corticosteroids and second-line therapies.\n\nThe study consists of a screening period, treatment period, end-of-treatment visit, safety follow-up, and study withdrawal visit. Two dose groups are planned: 2 mg and 4 mg, with 2 patients to be enrolled in each dose group. During the treatment period, JCXH-213 at the assigned dose will be administered once every other day for a total of 7 doses. Assessments for safety and efficacy will be conducted according to the study schedule. After the last dose, patients will undergo an end-of-treatment visit and safety follow-up until the end of the study.",[84],"Thrombocytopenic Purpura, Immune",[86,87,88],"JCXH-213","ITP","Primary Immune Thrombocytopenia (ITP) Refractory or Relapsed to Corticosteroids and Second-line Therapies","2026-05-27",{"date":91,"type":33},"2026-06-03",{"date":35,"type":20},{"date":94,"type":20},"2027-06-30",{"name":39,"class":40},{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":100,"acronym":4,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":21,"phases":104,"briefSummary":106,"conditions":107,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":41},"100630108","efficacy-and-safety-of-lusutrombopag-after-allogeneic-hematopoietic-stem-cell-transplantation-100630108","NCT07483385","Efficacy and Safety of Lusutrombopag After Allogeneic Hematopoietic Stem Cell Transplantation","Inclusion Criteria:\n\nParticipants must meet the following criteria:\n\n1. The patient signed an informed consent form and voluntarily participated in the study.\n2. Patients undergoing HLA haploidentical allogeneic hematopoietic stem cell transplantation;\n3. Age ≥18 years, regardless of gender\n4. ECOG score 0-2\n5. Expected survival ≥3 months\n6. No severe impairment of function of major organs\n\nExclusion Criteria:\n\nIf any of the following criteria are met, the participants must be excluded from this research project:\n\n1\\) Patients with known allergy to TPO-RAs; 2) Patients who cannot take oral medication due to gastrointestinal symptoms, altered mental status, etc. during transplantation; 3) Other reasons for exclusion as determined by the investigator.\n\n\\-",{"count":103,"type":20},45,[105],"NA","This study is an investigator-initiated prospective, single-center, open-label clinical trial designed to evaluate the clinical efficacy and safety of Lusutrombopag in promoting platelet remodeling after allogeneic hematopoietic stem cell transplantation in patients with hematologic disorders.",[108,109],"Patients With Hematologic Disorders After Allogeneic Hematopoietic Stem Cell Transplantation","Hematologic Disorders","2026-03-22",{"date":112,"type":33},"2026-03-25",{"date":114,"type":33},"2026-01-13",{"date":116,"type":20},"2028-01-28",{"name":39,"class":40},{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":125,"targetDuration":4,"studyType":21,"phases":127,"briefSummary":128,"conditions":129,"keywords":131,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":133,"lastUpdatePostDateStruct":134,"startDateStruct":136,"completionDateStruct":138,"leadSponsor":140,"locationsCount":4},"100608722","early-phase-1-aspirin-for-prevention-of-stroke-after-endovascular-aortic-arch-repair-a-multicenter-double-blind-randomized-controlled-trial-100608722","NCT07205250","Aspirin for Prevention of Stroke After Endovascular Aortic Arch Repair: a Multicenter, Double-Blind, Randomized Controlled Trial","WesternTheaterCommand","Inclusion Criteria:\n\n1. Adult patients aged 18 years or older;\n2. Diagnosed with type B or non-A non-B aortic dissection or thoracic aortic aneurysm according to the 2022 Chinese Expert Consensus on Stanford Type B Aortic Dissection;\n3. Underwent total endovascular aortic arch repair at the participating center with concurrent intraoperative endovascular reconstruction of supra-arch branch arteries;\n4. Signed the informed consent form and agreed to participate in this randomized controlled trial.\n\nExclusion Criteria\n\n1. Patients with known allergies to aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs);\n2. Patients with bleeding tendencies or active bleeding;\n3. Patients who used medications affecting coagulation (e.g., warfarin, antiplatelet drugs) within 30 days before surgery;\n4. Patients with a history of stroke;\n5. Patients undergoing concurrent additional surgical procedures during the operation;\n6. Patients with severe multi-organ dysfunction or other critical illnesses;\n7. Patients unable to comply with study protocols or complete postoperative follow-up;\n8. Patients participating in other drug or clinical studies that may interfere with the results of this research.",{"count":126,"type":20},224,[23],"ABSTRACT Introduction Endovascular aortic arch repair (EAAR) and the endovascular reconstruction of arch branch vessels represent a new trend in managing aortic arch pathologies, due to advantages such as minimal invasiveness, rapid recovery, and fewer complications. However, stroke is a common and serious complication during EAAR procedures. Strategies for its prevention, including the question of whether antiplatelet therapy should be administered postoperatively, have not yet been reported.\n\nMethods and analysis This project is designed as a prospective, multicenter, double-blind, randomized controlled trial. Patients undergoing Endovascular Aortic Arch Repair (EAAR) will be randomly assigned to three groups: aspirin treatment for 3 months, 6 months, or 1 year. All three groups will be followed up on for over one year. The primary endpoint is the incidence of postoperative stroke, while secondary endpoints include the patency rate of reconstructed supra-aortic branches, the incidence of major bleeding complications, EAAR-related complications, and the incidence of postoperative cognitive impairment. The study aims to evaluate the efficacy and safety of aspirin in preventing stroke after EAAR.\n\nFurthermore, stratified analyses will be conducted based on factors such as reconstruction techniques, the number of reconstructed branch arteries, and the diameter of branch stents to explore their impact on stroke incidence post-EAAR. The clinical utility of aspirin in different subgroups will also be assessed to provide more precise and personalized treatment strategies for clinical practice.\n\nEthics and dissemination This study has been approved by the Western Theater Command General Hospital and will be conducted in accordance with the principles of the Declaration of Helsinki. Ethical approval has been obtained separately from all participating research centers.\n\nSTRENGTHS AND LIMITATIONS OF THIS STUDY Endovascular aortic arch repair (EAAR) and endovascular reconstruction of the aortic arch branches have emerged as a new trend in managing aortic arch pathologies, owing to advantages such as minimal invasiveness, rapid recovery, and fewer complications. Stroke is a common and serious complication during EAAR procedures; however, strategies for its prevention, including the need for postoperative antiplatelet therapy, have not been well documented.\n\nThis project aims to conduct a prospective, multicenter randomized controlled trial to evaluate the efficacy and safety of aspirin in preventing stroke following EAAR, thereby providing evidence for clinical decision-making and improving long-term patient outcomes. As the trial will be conducted in China, where the population is predominantly Han Chinese, the generalizability of the findings may be limited.",[130],"Type B or Non-A Non-B Aortic Dissection;Thoracic Aortic Aneurysm",[132],"aspirin; stroke; endovascular aortic arch repair; prevention","2026-02-11",{"date":135,"type":33},"2026-02-12",{"date":137,"type":20},"2026-02-20",{"date":139,"type":20},"2028-09-20",{"name":39,"class":40},{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":148,"enrollmentInfo":149,"targetDuration":4,"studyType":21,"phases":151,"briefSummary":152,"conditions":153,"keywords":155,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":164,"locationsCount":41},"100614277","early-phase-1-autologous-bedside-cd19-car-t-cell-therapy-for-b-all-100614277","NCT07277504","Autologous Bedside CD19 CAR T-cell Therapy for B-ALL","Clinical Study on the Safety and Efficacy of Bedside CD19 CAR T-cell Therapy for B-cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Age 18 to 70 years inclusive at the time of signing informed consent.\n* Documented diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (2018, Version 1) or World Health Organization (WHO) classification criteria.\n* CD19 expression confirmed by flow cytometry, immunohistochemistry, or pathology on bone marrow, peripheral blood, or tissue specimens. For patients for whom current sampling is not clinically feasible, results from testing performed within 60 days prior to informed consent may be acceptable, as determined by the investigator.\n* Life expectancy ≥12 weeks in the opinion of the investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1, or 2.\n* Adequate organ function as demonstrated by the most recent assessment during the screening period, defined as:\n\n  * Creatinine clearance ≥60 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN)\n  * Total bilirubin ≤1.5 × ULN (for patients with documented Gilbert's syndrome, total bilirubin ≤2.5 × ULN is acceptable)\n* For women of childbearing potential (WOCBP), a negative serum pregnancy test must be documented within 7 days prior to enrollment. WOCBP and male patients with partners who are WOCBP must agree to use highly effective contraceptive methods from the screening period through 12 months after CAR-T cell infusion. Women are considered not of childbearing potential if they are postmenopausal for at least 1 year or have documented evidence of surgical sterilization or congenital infertility. Women who are pregnant or breastfeeding are excluded from this study.\n* Ability to understand and willingness to provide written informed consent prior to initiation of any study-specific procedures.\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, including long-term follow-up for up to 15 years.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria are not eligible for enrollment:\n\n* Active central nervous system (CNS) involvement by B-ALL, defined as CNS-2 or CNS-3 status according to standard criteria.\n* History of another malignancy within 2 years prior to screening, except for adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Patients who previously received CAR-T cell therapy and experienced Grade ≥4 cytokine release syndrome (CRS) or neurotoxicity are specifically excluded.\n* Treatment with any investigational or approved anti-B-ALL therapeutic agent within 5 half-lives prior to enrollment (excluding supportive care medications).\n* Radioimmunotherapy or radiotherapy within 8 weeks prior to enrollment.\n* Receipt of live attenuated vaccine within 4 weeks prior to screening.\n* Current or anticipated use of systemic corticosteroids at high dose (defined as a total cumulative dose equivalent to ≥60 mg dexamethasone or equivalent corticosteroid) within 4 weeks prior to lymphodepletion chemotherapy. Physiologic replacement doses, topical, inhaled, nasal, and ophthalmic corticosteroids are permitted.\n* Active acute or chronic graft-versus-host disease (GVHD) requiring systemic treatment within 4 weeks prior to CAR-T cell infusion.\n* Major surgical procedure within 3 months prior to screening.\n* Active CNS disorder or history of irreversible severe CNS toxicity from prior B-ALL therapy resulting in organic brain lesions or CNS dysfunction, including but not limited to seizure disorder, cerebrovascular accident, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\n* History of hypertensive crisis or hypertensive encephalopathy within 3 months prior to screening.\n* Any uncontrolled cardiovascular disease within 6 months prior to enrollment, or any of the following:\n\n  * Ventricular or atrial arrhythmia ≥Grade 2\n  * Bradycardia ≥Grade 2\n  * Myocardial infarction\n  * Severe or unstable angina pectoris\n  * Symptomatic congestive heart failure\n  * Cerebrovascular accident or transient ischemic attack\n  * Pulmonary embolism\n  * Deep vein thrombosis\n  * Poorly controlled hypertension despite standard medical management\n  * Left ventricular ejection fraction (LVEF) \\\u003C45% as assessed by echocardiography or multigated acquisition (MUGA) scan at screening\n* Any uncontrolled pulmonary disease within 6 months prior to enrollment, or any of the following:\n\n  * Pulmonary embolism\n  * Chronic obstructive pulmonary disease\n  * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis\n  * Evidence of active pneumonia on chest computed tomography (CT) scan at screening\n  * Symptomatic or uncontrolled interstitial lung disease\n  * Clinically significant pulmonary function abnormalities Note: History of radiation pneumonitis\u002Fpulmonary fibrosis in a radiation field is permitted if asymptomatic.\n* Active bacterial, fungal, protozoal, or viral infection that is not adequately controlled despite appropriate therapy at the time of enrollment, or positive blood culture within 7 days prior to enrollment.\n* Known active infection with any of the following:\n\n  * Hepatitis B virus (HBV): Positive HBV surface antigen (HBsAg) or HBV core antibody (HBcAb) with detectable HBV DNA above the normal range\n  * Hepatitis C virus (HCV): Positive HCV antibody with detectable HCV RNA above the normal range\n  * Human immunodeficiency virus (HIV): Positive HIV antibody\n  * Human T-lymphotropic virus (HTLV): Positive HTLV antibody\n  * Treponema pallidum (syphilis): Positive T. pallidum antibody\n  * Cytomegalovirus (CMV): Positive CMV DNA by polymerase chain reaction (PCR)\n* Legally incapacitated individuals under guardianship or conservatorship.\n* Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study or ability to provide informed consent.\n* Any abnormal finding, medical condition, or laboratory test result during screening that, in the investigator's judgment, may jeopardize patient safety or interfere with study conduct or interpretation of results.\n* Any planned medical or surgical intervention that would interfere with the conduct of the study.\n* Contraindication to any medication that may be required during the study, including but not limited to lymphodepletion chemotherapy agents (fludarabine, cyclophosphamide) and medications for management of adverse reactions (e.g., tocilizumab for CRS management, corticosteroids for ICANS management).","70 Years",{"count":150,"type":20},50,[23],"The purpose of this clinical trial is to learn if autologous bedside CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults. It will also learn about the safety and efficacy of the autologous bedside CD19 CAR-T cell product.\n\nThe main questions it aims to answer are:\n\n1. What adverse events occur and the incidence rate of dose-limiting toxicities (DLTs) within 28 days and CAR-T-related adverse events (AEs) after the autologous CD19 CAR-T cell infusion for B-ALL?\n2. Which dose level is the optimal biological dose (OBD)?\n3. What is the rate of minimal residual disease (MRD) negativity, complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), duration of response (DOR), and overall survival (OS)?\n\nParticipants will:\n\n1. Receive autologous bedside CD19 CAR T-cell therapy on Day 0.\n2. Be hospitalized for at least 7 days post-infusion for close safety monitoring and remain within 2 hours of the treatment facility for at least 28 days.\n3. Visit the clinic at Day 7, Day 14, Day 28, then monthly for up to 12 months after CAR-T cells infusion, with continued long-term follow-up for safety and persistence.",[154],"B-Cell Acute Lymphoblastic Leukemia, Adult",[60,156,157],"CAR T-cell therapy","B-ALL","2025-11-29",{"date":160,"type":33},"2025-12-11",{"date":162,"type":20},"2025-12-01",{"date":37,"type":20},{"name":39,"class":40},{"id":166,"slug":167,"hasResults":11,"nctId":168,"briefTitle":169,"officialTitle":170,"acronym":4,"eligibilityCriteria":171,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":148,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":176,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":181,"completionDateStruct":182,"leadSponsor":183,"locationsCount":41},"100612651","early-phase-1-allogeneic-ucb-derived-car-t-for-b-all-100612651","NCT07256353","Allogeneic UCB-derived CAR-T for B-ALL","Clinical Study on the Safety and Efficacy of Allogeneic, Umbilical Cord Blood Derived CAR T-cell Therapy for B Cell Acute Lymphoblastic Leukemia","Inclusion Criteria:\n\n* Age 18 to 70 years inclusive at the time of signing informed consent.\n* Documented diagnosis of B-cell acute lymphoblastic leukemia (B-ALL) according to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Acute Lymphoblastic Leukemia (2018, Version 1) or World Health Organization (WHO) classification criteria.\n* CD19 expression or CD20 confirmed by flow cytometry, immunohistochemistry, or pathology on bone marrow, peripheral blood, or tissue specimens. For patients for whom current sampling is not clinically feasible, results from testing performed within 60 days prior to informed consent may be acceptable, as determined by the investigator.\n* Life expectancy ≥8 weeks in the opinion of the investigator.\n* Eastern Cooperative Oncology Group (ECOG) performance status score \\\u003C4.\n* Adequate organ function as demonstrated by the most recent assessment during the screening period, defined as:\n\n  * Creatinine clearance ≥60 mL\u002Fmin (calculated using the Cockcroft-Gault formula)\n  * Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3 × upper limit of normal (ULN)\n  * Total bilirubin ≤- 1.5 × ULN (for patients with documented Gilbert's syndrome, total bilirubin ≤- 2.5 × ULN is acceptable)\n* For women of childbearing potential (WOCBP), a negative serum pregnancy test must be documented within 7 days prior to enrollment. WOCBP and male patients with partners who are WOCBP must agree to use highly effective contraceptive methods from the screening period through 12 months after CAR-T cell infusion. Women are considered not of childbearing potential if they are postmenopausal for at least 1 year or have documented evidence of surgical sterilization or congenital infertility. Women who are pregnant or breastfeeding are excluded from this study.\n* Ability to understand and willingness to provide written informed consent prior to initiation of any study-specific procedures.\n* Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures, including long-term follow-up for up to 15 years.\n\nExclusion Criteria:\n\n* Active central nervous system (CNS) involvement by B-ALL, defined as CNS-2 or CNS-3 status according to standard criteria.\n* History of another malignancy within 2 years prior to screening, except for adequately treated basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* Patients who previously received CAR-T cell therapy and experienced Grade ≥4 cytokine release syndrome (CRS) or neurotoxicity are specifically excluded.\n* Treatment with any investigational or approved anti-B-ALL therapeutic agent within 5 half-lives prior to enrollment (excluding supportive care medications).\n* Radioimmunotherapy or radiotherapy within 8 weeks prior to enrollment.\n* Receipt of live attenuated vaccine within 4 weeks prior to screening.\n* Current or anticipated use of systemic corticosteroids at high dose (defined as a total cumulative dose equivalent to ≥60 mg dexamethasone or equivalent corticosteroid) within 4 weeks prior to lymphodepletion chemotherapy. Physiologic replacement doses, topical, inhaled, nasal, and ophthalmic corticosteroids are permitted.\n* Active acute or chronic graft-versus-host disease (GVHD) requiring systemic treatment within 4 weeks prior to CAR-T cell infusion.\n* Major surgical procedure within 3 months prior to screening.\n* Active CNS disorder or history of irreversible severe CNS toxicity from prior B-ALL therapy resulting in organic brain lesions or CNS dysfunction, including but not limited to seizure disorder, cerebrovascular accident, severe brain injuries, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, or psychosis.\n* History of hypertensive crisis or hypertensive encephalopathy within 3 months prior to screening.\n* Any uncontrolled cardiovascular disease within 6 months prior to enrollment, or any of the following:\n\n  * Ventricular or atrial arrhythmia ≥Grade 2\n  * Bradycardia ≥Grade 2\n  * Myocardial infarction\n  * Severe or unstable angina pectoris\n  * Symptomatic congestive heart failure\n  * Cerebrovascular accident or transient ischemic attack\n  * Pulmonary embolism\n  * Deep vein thrombosis\n  * Poorly controlled hypertension despite standard medical management\n  * Left ventricular ejection fraction (LVEF) \\\u003C45% as assessed by echocardiography or multigated acquisition (MUGA) scan at screening Pulmonary Exclusions\n* Any uncontrolled pulmonary disease within 6 months prior to enrollment, or any of the following:\n\n  * Pulmonary embolism\n  * Chronic obstructive pulmonary disease\n  * History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis\n  * Evidence of active pneumonia on chest computed tomography (CT) scan at screening\n  * Symptomatic or uncontrolled interstitial lung disease\n  * Clinically significant pulmonary function abnormalities Note: History of radiation pneumonitis\u002Fpulmonary fibrosis in a radiation field is permitted if asymptomatic.\n* Active bacterial, fungal, protozoal, or viral infection that is not adequately controlled despite appropriate therapy at the time of enrollment, or positive blood culture within 7 days prior to enrollment.\n* Known active infection with any of the following:\n\n  * Hepatitis B virus (HBV): Positive HBV surface antigen (HBsAg) or HBV core antibody (HBcAb) with detectable HBV DNA above the normal range\n  * Hepatitis C virus (HCV): Positive HCV antibody with detectable HCV RNA above the normal range\n  * Human immunodeficiency virus (HIV): Positive HIV antibody\n  * Human T-lymphotropic virus (HTLV): Positive HTLV antibody\n  * Treponema pallidum (syphilis): Positive T. pallidum antibody\n  * Cytomegalovirus (CMV): Positive CMV DNA by polymerase chain reaction (PCR)\n* Legally incapacitated individuals under guardianship or conservatorship.\n* Psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study or ability to provide informed consent.\n* Any abnormal finding, medical condition, or laboratory test result during screening that, in the investigator's judgment, may jeopardize patient safety or interfere with study conduct or interpretation of results.\n* Any planned medical or surgical intervention that would interfere with the conduct of the study.\n* Contraindication to any medication that may be required during the study, including but not limited to lymphodepletion chemotherapy agents (fludarabine, cyclophosphamide) and medications for management of adverse reactions (e.g., tocilizumab for CRS management, corticosteroids for ICANS management).",{"count":150,"type":20},[23],"The purpose of this clinical trial is to learn if allogeneic, umbilical cord blood-derived chimeric antigen receptor T-cell (UCAR-T) therapy works to treat B-cell acute lymphoblastic leukemia (B-ALL) in adults. It will also learn about the safety and efficacy of the allogeneic, umbilical cord blood-derived CAR-T cell product.\n\nThe main questions it aims to answer are:\n\n1. What adverse events occur and the incidence rate of dose-limiting toxicities (DLTs) within 28 days and UCAR-T-related adverse events (AEs) after the UCAR-T cell infusion?\n2. Which dose level is the optimal biological dose (OBD)?\n3. What is the rate of minimal residual disease (MRD) negativity, complete remission (CR) or complete remission with incomplete hematologic recovery (CRi), duration of response (DOR), and overall survival (OS)?\n\nParticipants will:\n\n1. May receive lymphodepletion chemotherapy if clinically indicated: fludarabine (30 mg\u002Fm²\u002Fd, days -5, -4, and -3) and cyclophosphamide (300-500 mg\u002Fm²\u002Fd, days -5 and -4).\n2. If lymphodepletion chemotherapy is administered, rest for 2 days on Day -2 and Day -1.\n3. Receive UCAR-T cells infusion on Day 0.\n4. Be hospitalized for at least 7 days post-infusion for close safety monitoring and remain within 2 hours of the treatment facility for at least 28 days.\n5. Visit the clinic at Day 7, Day 14, Day 28, then monthly for up to 12 months after UCAR-T cells infusion, with continued long-term follow-up for safety and persistence.",[154],[177,178,157],"allogeneic CAR-T","umbilical cord blood-derived","2025-11-20",{"date":162,"type":33},{"date":162,"type":20},{"date":37,"type":20},{"name":39,"class":40},{"id":185,"slug":186,"hasResults":11,"nctId":187,"briefTitle":188,"officialTitle":189,"acronym":4,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":16,"minAge":191,"maxAge":49,"enrollmentInfo":192,"targetDuration":4,"studyType":21,"phases":194,"briefSummary":195,"conditions":196,"keywords":198,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":201,"lastUpdatePostDateStruct":202,"startDateStruct":204,"completionDateStruct":206,"leadSponsor":208,"locationsCount":41},"100568700","early-phase-1-a-study-on-the-efficacy-of-gd2-car-t-cells-in-the-treatment-of-neuroblastoma-100568700","NCT06684639","A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma","An Open Clinical Study on the Safety and Efficacy of Autologous GD2-CAR T Cells in the Treatment of Relapsed Refractory Neuroblastoma","Inclusion Criteria:\n\n1. All cases were diagnosed as neuroblastoma with positive expression of GD2 antigen in tumor cells. Informed consent of patient or guardian.\n2. Diagnosis of recurrent\u002Frefractory neuroblastoma.\n3. At least 2 weeks or 5 half-lives (whichever is shorter) from the beginning of preconditioning chemotherapy after prior systemic treatment.\n4. Toxic reactions caused by previous antitumor therapy must be stabilized and restored to ≤ grade 1.\n5. Over 1 years old, under 18 years old.\n6. Physical strength score 0-3 (ECOG standard).\n7. No obvious active infection.\n8. Expected survival ≥3 months\n9. Adequate kidney, liver, lung and heart function, defined as creatinine clearance (estimated by the Cockcroft Gault formula) \\> 60 mL\u002Fmin; Serum ALT\u002FAST ≤ 2.5 ULN; Total bilirubin ≤1.5 ULN, excluding subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 50%, echocardiography confirmed centropericardial effusion, and ECG showed no clinically significant abnormal findings. There was no clinically significant pleural effusion. Baseline blood oxygen saturation under indoor ventilation was \\> 92%.\n10. The serum pregnancy test results of fertile women must be negative (women who have undergone surgical sterilization or at least 2 years after menopause are considered to be infertile).\n\nExclusion Criteria:\n\n1. The subject has had other malignancies, non-melanoma skin tumors, carcinoma in situ (e.g. Cervix, bladder, breast), unless disease-free survival of at least 3 years.\n2. There is an uncontrollable infection, including fungal, bacterial, viral or other.\n3. Known human immunodeficiency virus (HIV) infection.\n4. Known history of hepatitis B (HBsAg positive) or hepatitis C (HCV antibody positive). Subjects with latent or prehepatitis B infection (defined as HBcAb positive and HBsAg negative) can be enrolled only if PCR tests for HBV DNA are negative. In addition, these subjects were required to undergo a monthly PCR test for HBV DNA. Participants who are serologically positive for HCV antibodies can also be enrolled if their PCR test results for HCV RNA are negative.\n5. Existing or past CNS disease, such as seizures, cerebrovascular ischemia\u002Fbleeding, dementia, cerebellar disease, or any CNS-related autoimmune disease.\n6. Serious heart disease, such as uncontrolled or symptomatic arrhythmia, congestive heart failure, or myocardial infarction within 6 months prior to screening, or any grade 3 (moderate) or 4 (severe) heart disease (according to the New York Heart Society Functional Grading Method NYHA).\n7. A history of myocardial infarction, angioplasty or stent placement, unstable angina pectoris, or other clinically significant heart disease in the 12 months prior to enrollment.\n8. Any medical condition that may affect the evaluation of safety or efficacy.\n9. Have had severe rapid hypersensitivity reactions to any of the drugs to be used in this study.\n10. Live vaccine should be administered within ≤6 weeks before starting the pretreatment regimen.\n11. Pregnant or lactating female subjects.\n12. Male or female subjects who do not consent to effective contraception from the time they sign informed consent until 6 months after completing immune cell therapy.\n13. Subjects judged by the investigator had difficulty in completing all visits or procedures required by the study protocol (including follow-up visits), or were not compliant enough to participate in the study.","1 Year",{"count":193,"type":20},30,[23],"Neuroblastoma (NB) is a malignant tumor of the sympathetic nervous system.Chemotherapy and autologous hematopoietic stem cell transplantation are the main treatments for neuroblastoma, and the prognosis of patients with high-risk recurrence and refractory treatment is very poor. There is a large unmet medical need in patients with relapsed refractory neuroblastoma, and further research into new therapeutic approaches is needed for these patients.GD2 is a dissialic ganglioside expressed by neuroectodermal tumors. The proportion of GD2 expression in neuroblastoma is up to 100%, so GD2 is a specific target for neuroblastoma immunotherapy and an ideal target for CAR-T treatment of neuroblastoma.",[197],"Neuroblastoma",[197,199,200],"Relapsed","Refractory","2024-12-18",{"date":203,"type":33},"2024-12-20",{"date":205,"type":33},"2024-12-01",{"date":207,"type":20},"2030-12-01",{"name":39,"class":40},{"id":210,"slug":211,"hasResults":11,"nctId":212,"briefTitle":213,"officialTitle":214,"acronym":4,"eligibilityCriteria":215,"healthyVolunteers":216,"sex":16,"minAge":49,"maxAge":77,"enrollmentInfo":217,"targetDuration":4,"studyType":21,"phases":219,"briefSummary":221,"conditions":222,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":224,"lastUpdatePostDateStruct":225,"startDateStruct":227,"completionDateStruct":229,"leadSponsor":231,"locationsCount":41},"100563227","phase-4-clinical-study-of-combined-platelet-transfusion-100563227","NCT06613425","Clinical Study of Combined Platelet Transfusion","Combined Platelet Transfusion:A Single-arm, Open, Prospective, Non-inferiority Clinical Trial","Inclusion Criteria:\n\n* 1\\. Aged 18-65 years; 2. Disease treatment in the research hospital; 3. Applied for platelet transfusion therapy.\n\nExclusion Criteria:\n\n* 1\\. One month before the start of this study, he participated in other clinical trials of drugs and instruments related to platelet transfusion efficacy; 2. Without platelet transfusion indications; 3. Only received platelet transfusion in the outpatient department and left the hospital without efficacy evaluation after transfusion; 4. Gave up platelet transfusion therapy for any reason after enrollment; 5. Transferred or discharged from hospital for any reason before platelet transfusion after enrollment; 6. Did not receive combined platelet transfusion during the 6-month treatment period after enrollment",true,{"count":218,"type":20},86,[220],"PHASE4","Platelet transfusion is an irreplaceable and important treatment method for clinical prevention and treatment of thrombocytopenia or platelet dysfunction. Due to various factors, it is difficult to achieve platelet ABO complete homotypic transfusion in clinical practice. When ABO-compatible platelets cannot be obtained, plasma-reduced platelets, platelets with low anti-A or anti-B titers are often used in clinical practice to reduce the risk of ABO-incompatible platelet-compatible transfusion reactions. The combined platelets prepared in this study can achieve ABO primary and secondary side compatible infusion.",[223],"Hematologic Diseases","2024-09-23",{"date":226,"type":33},"2024-09-26",{"date":228,"type":33},"2024-08-01",{"date":230,"type":20},"2025-10-28",{"name":39,"class":40},{"id":233,"slug":234,"hasResults":11,"nctId":235,"briefTitle":236,"officialTitle":237,"acronym":238,"eligibilityCriteria":239,"healthyVolunteers":11,"sex":16,"minAge":49,"maxAge":4,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":249,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":264,"completionDateStruct":266,"leadSponsor":268,"locationsCount":41},"100562144","effects-of-mesenchymal-stem-cell-supernatant-on-prevention-and-treatment-of-skinmucosal-injury-in-hematology-patients-100562144","NCT06599346","Effects of Mesenchymal Stem Cell Supernatant on Prevention and Treatment of Skin\u002FMucosal Injury in Hematology Patients","Study on the Effects of Mesenchymal Stem Cell Culture Supernatant on the Prevention and Treatment of Mucosal Injury in Hematology Patients","MSC-MucInj","Inclusion Criteria:\n\n* Participants aged 18 years or older.\n* Patients who have undergone hematopoietic stem cell transplantation (HSCT).\n* Patients who have developed mucosal injuries (oral, skin, or bladder) after HSCT, chemotherapy, or radiotherapy.\n* Patients who are willing to provide informed consent and comply with the study procedures.\n\nExclusion Criteria:\n\n* Patients with severe organ dysfunction (e.g., heart, liver, kidney failure) that could interfere with the study.\n* Patients with uncontrolled active infections.\n* Known allergies or hypersensitivity to MSC supernatant.\n* Pregnant or breastfeeding women.\n* Patients with HIV or active hepatitis B or C infections.\n* Patients who have participated in another clinical trial within the last 4 weeks.",{"count":241,"type":20},120,[105],"This clinical trial is studying the effects of mesenchymal stem cell (MSC) culture supernatant on the prevention and treatment of mucosal injuries in patients undergoing hematopoietic stem cell transplantation (HSCT). HSCT is a common treatment for blood-related cancers and other serious blood disorders. However, many patients experience severe damage to their mucous membranes, including the lining of the mouth, skin, and bladder, due to the high-dose chemotherapy used in the treatment process. These mucosal injuries can cause pain, increase the risk of infection, and lower the patient's quality of life.\n\nThe purpose of this study is to determine whether MSC culture supernatant can help repair mucosal injuries and improve recovery for these patients. MSC culture supernatant contains substances produced by mesenchymal stem cells that may promote healing and reduce inflammation. These substances could potentially repair tissue without the risks associated with using live cells.\n\nParticipants in this trial will be randomly assigned to one of two groups: one group will receive standard care, and the other will receive MSC culture supernatant as part of their treatment. The study will look at how well MSC supernatant helps heal mucosal injuries, as well as its safety and any side effects that may occur. The outcomes of this study could lead to new ways to prevent and treat mucosal injuries in patients undergoing HSCT, improving their quality of life during and after treatment.\n\nThe trial will include 120 patients who have undergone HSCT and experienced mucosal injuries. The study will last approximately five years, from October 2020 to September 2025. Participants will be monitored throughout the trial for safety and effectiveness of the treatment, with follow-up visits scheduled to assess their progress.",[245,246,247,248],"Mucositis","Hematopoietic Stem Cell Transplantation","Chemotherapy-Induced Mucositis","Radiation-Induced Mucositis",[250,251,252,246,253,254,255,256,257,258,259,260],"Mesenchymal Stem Cell Supernatant","Mesenchymal Stem Cell Exosomes","Mucosal Injury","Chemotherapy","Radiotherapy","Oral Mucosal Injury","Skin Mucosal Injury","Bladder Injury","HSCT Complications","Tissue Regeneration","Mucosal Repair","2024-09-14",{"date":263,"type":33},"2024-09-19",{"date":265,"type":33},"2020-10-01",{"date":267,"type":20},"2025-09-30",{"name":39,"class":40},{"id":270,"slug":271,"hasResults":11,"nctId":272,"briefTitle":273,"officialTitle":273,"acronym":4,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":77,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":277,"briefSummary":279,"conditions":280,"keywords":282,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":41},"100561068","phase-1-clinical-study-on-the-safety-and-efficacy-of-cd7-car-t-cell-in-patients-with-relapsedrefractory-acute-leukemia-100561068","NCT06585345","Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell in Patients With Relapsed\u002FRefractory Acute Leukemia","Inclusion Criteria:\n\n1. Patients diagnosed with acute leukemia.\n2. Acute leukemia complex\u002Frefractory cases with poor response to conventional chemotherapy: 1) patients who did not achieve complete remission after 2 courses of treatment with standard induced remission regimen; 2) Recurrence within 6 months after the first remission; 3) Relapse 6 months after the first remission, but failure to be treated again with the original induced remission regimen; 4) Recurrent patients.\n3. At least 2 weeks or 5 half-lives (whichever is shorter) from the start of preconditioning chemotherapy after prior systemic treatment, except for immune checkpoint inhibitors\u002Fagonists; Systemic immune checkpoint inhibitor\u002Fagonist treatment is at least 3 half-lives away from pre-treatment chemotherapy (e.g., ipilimumab, etc.).\n4. Toxic reactions caused by previous antitumor therapy must be stabilized and returned to ≤ grade 1 (except for clinically insignificant toxicity, such as baldness).\n5. Over 14 years old, under 65 years old.\n6. Physical Strength score 0-3 (ECOG standard)\n7. No obvious active infection or graft-versus-host disease\n8. Expected survival ≥3 months\n9. Adequate kidney, liver, lung and heart function, defined as:\n\n   Creatinine clearance (estimated by Cockcroft Gault formula) \\> 60 mL\u002Fmin; Serum ALT\u002FAST ≤ 2.5 ULN; Total bilirubin ≤1.5 ULN, excluding subjects with Gilbert's syndrome; Cardiac ejection fraction ≥ 50%, echocardiography confirmed centropericardial effusion, and ECG showed no clinically significant abnormal findings.\n\n   There was no clinically significant pleural effusion. Baseline blood oxygen saturation under indoor ventilation was \\> 92%.\n10. The serum pregnancy test results of fertile women must be negative (women who have undergone surgical sterilization or at least 2 years after menopause are considered to be infertile).\n\nExclusion Criteria:\n\n1. The subject has had other malignancies, non-melanoma skin tumors, carcinoma in situ (e.g. Cervix, bladder, breast), unless disease-free survival of at least 3 years\n2. Presence or suspicion of uncontrollable fungal, bacterial, viral or other infections.\n3. Known human immunodeficiency virus (HIV) infection\n4. Known history of hepatitis B (HBsAg positive) or hepatitis C (HCV antibody positive). Subjects with latent or prehepatitis B infection (defined as HBcAb positive and HBsAg negative) can be enrolled only if PCR tests for HBV DNA are negative. In addition, these subjects were required to undergo a monthly PCR test for HBV DNA. Participants who are serologically positive for HCV antibodies can also be enrolled if their PCR test results for HCV RNA are negative.\n5. Existing or past CNS disease, such as seizures, cerebrovascular ischemia\u002Fbleeding, dementia, cerebellar disease, or any CNS-related autoimmune disease\n6. Subjects with severe heart disease, such as uncontrolled or symptomatic arrhythmias, congestive heart failure, or myocardial infarction within 6 months prior to screening, or any grade 3 (moderate) or 4 (severe) heart disease (according to the New York Heart Society Functional Grading Method NYHA) with lymphoma infiltrating the heart's atria or ventricles\n7. A history of myocardial infarction, angioplasty or stent placement, unstable angina pectoris, or other clinically significant heart disease in the 12 months prior to enrollment\n8. Emergency treatment is expected or likely to occur within 6 weeks due to rapid tumor progression (e.g. tumor mass compression)\n9. Primary immune deficiency\n10. History of symptomatic deep vein thrombosis or pulmonary embolism within 6 months prior to enrollment\n11. Any medical condition that may affect the evaluation of safety or efficacy\n12. Have had severe rapid hypersensitivity reactions to any of the drugs to be used in this study\n13. Administer live vaccine within ≤6 weeks prior to initiation of the pretreatment regimen\n14. Pregnant or lactating female subjects\n15. Male or female subjects who do not consent to effective contraception from the time they sign informed consent until 6 months after completing AT19 treatment\n16. Subjects judged by the investigator had difficulty completing all visits or procedures required by the study protocol (including follow-up visits), or were not compliant enough to participate in the study\n17. In the past 2 years, subjects have had other malignancies, non-melanoma skin tumors, carcinoma in situ (e.g. Cervix, bladder, breast), end-organ damage due to autoimmune diseases (e.g. Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus), or need to systematically administer immunosuppressive or other drugs for systemic disease control. Unless disease free survival of at least 3 years\n18. Participate in other clinical experimenters during the same period",{"count":276,"type":20},200,[81,278],"PHASE2","Acute leukemia is a malignant clonal disease of hematopoietic stem cells. At present, the treatment for acute leukemia is relatively limited, and it is still based on high-intensity chemotherapy drug therapy and hematopoietic stem cell transplantation. The prognosis of recurrent and refractory acute leukemia is poor, and there is a lack of effective treatment plan. CD7 is a specific target on the surface of T cells, and CD7 CAR-T is expected to provide a new therapeutic path for patients with relapsed refractory acute leukemia.This is an open, single-arm, single-center, prospective clinical study. The main objective of the clinical study is to evaluate the clinical safety and tolerability of CD7 CAR-T in the treatment of acute leukemia.",[281],"Acute-Leukemia",[281,199,200],"2024-09-02",{"date":285,"type":33},"2024-09-05",{"date":287,"type":33},"2024-02-18",{"date":289,"type":20},"2030-11-01",{"name":39,"class":40},""]